University of Arizona Not Only Showcases Potential of Aliskiren for Extending Survival in Heart Failure but Also Files Patent for New Way to Measure Edema

University of Arizona Not Only Showcases Potential of Aliskiren for Extending Survival in Heart Failure but Also Files Patent for New Way to Measure Edema

Preclinical research at the University of Arizona College of Medicine—Phoenix reveals that Aliskren, a drug that inhibits the enzyme that regulates blood pressure, can delay the progression of congestive heart failure and lengthen survival rates. The team also...

Pin It on Pinterest